CoChat

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Association of eszopiclone, zaleplon, or zolpidem with complex sleep behaviors resulting in serious injuries, including death

Harbourt, Kelly, Nevo, Ofir N., Zhang, Rongmei, Chan, Vicky, Croteau, David · 2020 · Pharmacoepidemiology and Drug Safety

Abstract

PURPOSE: To identify and analyze postmarketing cases of complex sleep behaviors (CSBs) resulting in serious injuries, including death, associated with eszopiclone, zaleplon, or zolpidem (Z-drugs). METHODS: Retrospective analysis of the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) from 16 December 1992 through 27 February 2018 and medical literature using PubMed and EMBASE. We used random sampling and descriptive statistics. RESULTS: We identified 66 cases that met inclusion and exclusion criteria, four of which were identified in the medical literature. Twenty cases reported death and 46 cases reported serious injuries in association with CSBs occurring after the use of a Z-drug. Fatal cases described events, such as carbon monoxide poisoning, drowning, falls, hypothermia, motor vehicle collisions, and apparent completed suicide. Nonfatal cases resulting in serious injuries described events, such as accidental overdoses, falls, gunshot wounds, hypothermia, third-degree burns, and self-injuries or suicide attempts. Twenty-two cases reported a previous episode of a CSB while taking a Z-drug prior to the event reported in this case series. CONCLUSIONS: The FAERS and medical literature cases support the need for increased awareness of the consequences that may occur because of CSBs associated with the use of Z-drugs. Therefore, to protect public health, regulatory actions were taken, including adding a Boxed Warning, a Contraindication in patients who have experienced a prior episode of a CSB with a Z-drug, and updating the existing Warnings and Precautions. An FDA Drug Safety Communication was also disseminated to alert healthcare professionals and the public of this potential risk.

Overview

Integrity signals

Registry

Crossref · 10.1002/pds.5004

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 18 references

Research works printed but not linked: 2

  1. Southworth MR. Zaleplon Eszopiclone and Zolpidem and Sleep Driving. FDA ODS Postmarketing Safety Review: PID # D060196;2006.
  2. U.S. Food and Drug Administration. Code of Federal Regulations Title 21 Volume 5 Chapter 1 Section 314.80 Postmarketing reporting of adverse drug experiences. Revised as of April 1 2018.

Cited by

See all 46

Metadata

Authors
Harbourt, K., Nevo, O. N., Zhang, R., Chan, V., & Croteau, D.
Affiliations
United States Food and Drug Administration (US)
Corresponding author
Harbourt, Kelly
Venue
Pharmacoepidemiology and Drug Safety
Publisher
Wiley
Published
2020-04-22
Volume
29
Issue
6
Pages
684-691
ISSN
  • 1053-8569 (ISSN-L)
  • 1099-1557
OpenAlex
W3019649063
Cited by
46
References
18
Citations by year
2026: 10 · 2025: 10 · 2024: 4 · 2023: 9 · 2022: 7 · 2021: 4 · 2020: 2
FWCI
3.86
Type
journal article
Language
en
Open access
closed
Locations
  • Pharmacoepidemiology and Drug Safety (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
  • Health Sciences › Medicine › Emergency Medicine › Poisoning and overdose treatments
Keywords
eszopiclone, zaleplon, zolpidem, Z-drugs, sleep-related injury, carbon monoxide poisoning, drowning, falls, accidental overdose, suicide attempts, adverse drug reactions, drug safety communication, black box warning, FDA Adverse Event Reporting System
MeSH terms
Sleep Aids, Pharmaceutical, Eszopiclone, Zolpidem, Acetamides, Adult, Aged, Drug Labeling, Female, Humans, Sleep Initiation and Maintenance Disorders, Male, Middle Aged, Pyrimidines, Retrospective Studies, Risk Factors, Sleep, Somnambulism, Time Factors, Wounds and Injuries, Treatment Outcome, Adverse Drug Reaction Reporting Systems, Risk Assessment, Parasomnias

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.